|
SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes
|
Jun 2020
|
Clinical Lymphoma , Myeloma & Leukemia
|
myelodysplastic syndromes (MDS)
|
|
PNH Phenotypes and Their Genesis
|
Jun 2020
|
British Journal of Haematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
In Search for a Haemoglobin Threshold in Myelodysplastic Syndromes
|
Jun 2020
|
British Journal of Haematology
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic Syndromes: A Review of Therapeutic Progress Over the Past 10 Years
|
Jun 2020
|
Expert Review of Anticancer Therapy
|
myelodysplastic syndromes (MDS)
|
|
Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS
|
Jun 2020
|
Leukemia
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity?
|
Jun 2020
|
Best practice & research. Clinical haematology
|
myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN)
|
|
Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro
|
Jun 2020
|
Experimental Hematology
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia
|
Jun 2020
|
Haematologica
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Controversies on the Consequences of Iron Overload and Chelation in MDS
|
May 2020
|
HemaSphere
|
myelodysplastic syndromes (MDS)
|
|
How I Diagnose Low-Grade Myelodysplastic Syndromes
|
May 2020
|
American Journal of clinical Pathology
|
myelodysplastic syndromes (MDS)
|
